Cover Image
市場調查報告書

黑皮質素4受體:開發中產品分析

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 359406
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
黑皮質素4受體:開發中產品分析 Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 65 Pages
簡介

本報告提供黑皮質素4受體的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

黑皮質素4受體概要

治療藥的開發

黑皮質素4受體:開發中的產品 - 各開發階段

黑皮質素4受體:開發中的產品 - 各治療範圍

黑皮質素4受體開發中的產品 - 各適應症

黑皮質素4受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

黑皮質素4受體:企業開發中的產品

黑皮質素4受體:大學/機關開發中的產品

黑皮質素4受體:治療藥的評估

  • 單劑產品
  • 各產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

黑皮質素4受體的治療藥開發企業

  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Retrophin Inc.
  • Rhythm Pharmaceuticals, Inc.

黑皮質素4受體:藥物簡介

黑皮質素4受體:暫停中的計劃

黑皮質素4受體:開發中止的產品

黑皮質素4受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0539TDB

Summary

Global Markets Direct's, 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016', provides in depth analysis on Melanocortin Receptor 4 (MC4R) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanocortin Receptor 4 (MC4R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
  • The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Melanocortin Receptor 4 (MC4R) Overview
  • Therapeutics Development
    • Melanocortin Receptor 4 (MC4R) - Products under Development by Stage of Development
    • Melanocortin Receptor 4 (MC4R) - Products under Development by Therapy Area
    • Melanocortin Receptor 4 (MC4R) - Products under Development by Indication
  • Melanocortin Receptor 4 (MC4R) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Melanocortin Receptor 4 (MC4R) - Products under Development by Companies
  • Melanocortin Receptor 4 (MC4R) - Products under Development by Universities/Institutes
  • Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Mallinckrodt Plc
    • Obexia AG
    • Palatin Technologies, Inc.
    • Pfizer Inc.
    • Retrophin Inc.
  • Melanocortin Receptor 4 (MC4R) - Drug Profiles
    • (liraglutide + setmelanotide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQB-565 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bremelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corticotropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cosyntropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBX-1201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-8905 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proteins to Agonize MC4R for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setmelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize MC4-R for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Melanocortin Receptor 4 (MC4R) - Dormant Projects
  • Melanocortin Receptor 4 (MC4R) - Discontinued Products
  • Melanocortin Receptor 4 (MC4R) - Featured News & Press Releases
    • Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
    • Jul 20, 2016: Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
    • Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse
    • Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies' New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors
    • Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus
    • Jun 06, 2016: Palatin Technologies Receives U.S. Patent Strengthening Its Melanocortin Peptide Intellectual Property
    • May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome
    • Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting
    • Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
    • Jan 07, 2016: Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity
    • Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome
    • Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
    • Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus
    • Nov 06, 2015: Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity
    • Nov 06, 2015: Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AstraZeneca Plc, H2 2016
  • Pipeline by Mallinckrodt Plc, H2 2016
  • Pipeline by Obexia AG, H2 2016
  • Pipeline by Palatin Technologies, Inc., H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Retrophin Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top